Peer-reviewed veterinary case report
How molnupiravir helps cats with infectious peritonitis over time
By Yoshida, Shino et al.·Published in The Canadian veterinary journal = La revue veterinaire canadienne·2025·Department of Small Animal Clinical Sciences, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of the course of improvement with molnupiravir treatment for feline infectious peritonitis.
- Species:
- cat
Plain-English summary
Eleven cats diagnosed with feline infectious peritonitis (FIP) were treated with a medication called molnupiravir to see how well it worked. Most of the cats showed improvement, with symptoms like lethargy and high levels of a protein indicating inflammation resolving within 15 days. However, one cat sadly passed away after 11 days, while the others completed an 84-day treatment course without any relapses. For those with neurological symptoms, the dosage was increased, and they were monitored closely. Overall, the treatment appeared effective for most cats, leading to a positive outcome.
People also search for: cat FIP treatment · molnupiravir for cats · feline infectious peritonitis symptoms · cat lethargy treatment
Abstract
OBJECTIVE: To clarify the clinical course during molnupiravir treatment for feline infectious peritonitis (FIP). ANIMALS AND PROCEDURE: Cats diagnosed with FIP and treated with molnupiravir at Hokkaido University Veterinary Teaching Hospital (Sapporo, Hokkaido, Japan) were retrospectively reviewed. RESULTS: Eleven cats were eligible for inclusion. Six cats had effusive FIP and 5 had non-effusive FIP. In noneffusive cases, 2 cats had neurological abnormalities at diagnosis, whereas 1 additional cat developed neurological signs during treatment. The median initial dosage of molnupiravir was 13.0 mg/kg (range: 10.0 to 15.0 mg/kg), PO, q12h. One cat died after 11 d and the remaining 10 cats completed an 84-day course of treatment. All neurological cases were given dosage increases, extended treatment duration, or both. The median final dosage of molnupiravir in non-neuro-FIP cases was 13.1 mg/kg (range: 10.0 to 15.0 mg/kg), PO, q12h, whereas dosages in neuro-FIP cases were 15.0, 15.2, and 17.2 mg/kg, PO, q12h in the 3 affected cats, respectively. In non-neurological cases, dysrexia, lethargy, and high serum amyloid A were resolved within 15 d. Total follow-up duration ranged from 175 to 362 d. No relapses were observed. CONCLUSION AND CLINICAL RELEVANCE: Monitoring responses to molnupiravir treatment requires observing clinical signs and conducting clinicopathological evaluations, including acute-phase protein evaluation.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40322652/